Table 2 Altered metabolites with an average VIP score greater than 1.0 from the PLS-DA comparing manifest HD patients (HD) with controls (C).

From: Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington’s disease subjects

Metabolite

HMDB

VIP mean(95% CI)

log2 FC HD-C

p-value

FDR

Validation level

Lumichrome

—

2.56(2.47, 2.64)

−1.02

6.3 × 10 −3

0.047

2

Xanthine*

HMDB00292

2.33(2.28, 2.38)

0.28

3.9 × 10 −3

0.047

2

O-succinyl-homoserine*

YMDB00917

1.94(1.83, 2.05)

−0.38

0.043

0.101

1

N-acetylproline*

—

1.90(1.81, 1.99)

0.25

6.0 × 10 −3

0.047

1

Phenylacetate

HMDB00209

1.81(1.72, 1.90)

0.20

0.030

0.100

2

Isoleucine

HMDB00172

1.81(1.72, 1.89)

−0.51

7.8 × 10 −3

0.047

2

L-DOPA

HMDB00181

1.77(1.69, 1.86)

−0.34

0.015

0.070

1

Leucine

HMDB00687

1.76(1.66, 1.86)

−0.23

0.033

0.100

2

Corticosterone

HMDB01547

1.52(1.40, 1.64)

−0.70

0.066

0.101

1

Ophthalmate

HMDB05765

1.44(1.35, 1.53)

−0.34

0.065

0.101

1

Salicylate

HMDB01895

1.42(1.33, 1.51)

−0.46

0.031

0.100

1

Phenylalanine

HMDB00159

1.42(1.31, 1.52)

−0.12

0.087

0.116

2

Deoxyuridine

HMDB00012

1.36(1.27, 1.46)

−0.20

0.075

0.106

1

Valine

HMDB00883

1.33(1.24, 1.43)

−0.16

0.059

0.101

2

Creatinine

HMDB00562

1.33(1.23, 1.42)

0.16

0.053

0.101

2

Inosine

HMDB00195

1.32(1.22, 1.43)

0.14

0.147

0.160

2

Cyclic AMP

HMDB00058

1.31(1.19, 1.42)

0.21

0.106

0.127

1

Hypoxanthine

HMDB00157

1.29(1.23, 1.36)

0.20

0.059

0.101

2

Glutarylcarnitine*

HMDB13130

1.24(1.16, 1.33)

−0.24

0.114

0.130

2

Phosphocreatine

HMDB01511

1.16(1.08, 1.25)

0.27

0.067

0.101

1

Aldosterone/Cortisone

—/HMDB02802

1.13(1.07, 1.19)

−0.36

0.044

0.101

1

Tyrosine*

HMDB00158

1.13(1.04, 1.21)

−0.11

0.095

0.120

2

5-methylcytosine*

HMDB02894

1.11(1.01, 1.22)

0.11

0.163

0.170

1

1-methyladenosine

HMDB03331

1.02(0.91, 1.13)

−0.45

0.198

0.198

1

  1. A positive log2 fold change (FC) HD-C indicates an increase in manifest HD patients compared with controls and vice versa. p-values < 0.05 and FDR values < 0.1 have been bolded. *Metabolites with a demonstrated age dependence that have been corrected. Identities confirmed by m/z and elution time of the internal standards and by MS/MS fragmentation pattern (validation level 2). Identities confirmed by m/z and elution time of the internal standards (validation level 1).
Back to article page